Clinical Trial Update: "Receptor Radionuclide Therapy With 177Lu-DOTATOC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating receptor radionuclide therapy with 177Lu-DOTATOC for neuroendocrine tumors, including paraganglioma and pheochromocytoma, is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors
• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• 177Lu-DOTATOC (Lutetium-177 DOTATOC)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Neuroendocrine Tumors, Paraganglioma | Phase 2 | Status: RECRUITING